<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347966">
  <stage>Registered</stage>
  <submitdate>17/01/2012</submitdate>
  <approvaldate>18/01/2012</approvaldate>
  <actrnumber>ACTRN12612000093886</actrnumber>
  <trial_identification>
    <studytitle>Prostaglandin gel versus oxytocin for induction of labour in term prelabour rupture of membranes</studytitle>
    <scientifictitle>For women with term prelabour rupture of membranes who wish active management does use of PG gel result in better satisfaction and less need for oxytocin without increasing risk of neonatal sepsis.</scientifictitle>
    <utrn />
    <trialacronym>PO PROM</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>term prelabour rupture of membranes</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Three doses of Prostaglandin F2 alpha gel 6 hours apart = first dose after obtaining consent

doses are 2mg each time for nulliparous women and 1mg initially and then 2 mg for multiparous women

gel will be inserted vaginally</interventions>
    <comparator>Oxytocin infusion - standard regime used in B/sute for induction of labour - commencing as soon as consented and a bed available in b/suite.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>onset of labour without need for further oxytocin</outcome>
      <timepoint>in labour</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>need fo augmentation with oxytocin - these will be assessed by review of charts after birth</outcome>
      <timepoint>in labour</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of epidural</outcome>
      <timepoint>in labour</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>c/section rate</outcome>
      <timepoint>at birth</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>chorioamnionitis - assessed by review of charts - these are clincal diagnoses</outcome>
      <timepoint>during hospiotal stay or readmission within 6 weeks of delivery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>neonatal sepsis - confirmed or suspected - as charted in the babys chart</outcome>
      <timepoint>whilst in hospital or needing readmission with such a diagnosis within 6 weeks of birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>gestational age &gt;36 weeks and 6 days
Confirmed SROM
Singleton pregnancy
live fetus
cephalic presentation
informed consent</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>severe medical problem
compromised fetus
indication for immediate delivery
suspected sepsis
previous c/section
known gbs infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>all eligible women will be provided with written information on the study

after about an hour they will be approached to answer any questions

if willing to participate women will sign consent and an allocation will be performed.</concealment>
    <sequence>computer generated random table - equal blocks  - allocation by research staff not involvd in clinical care - sequentaiily numbered sealed opaque enevelopes will contain the allocation

envelope will only be opened after signed consent</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>nil</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>10/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>280</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>ipswich Hospital</primarysponsorname>
    <primarysponsoraddress>P O Box 73 
Ipswich 
Qld
4305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>kassam Mahomed</sponsorname>
      <sponsoraddress>P O Box 73 
Ipswich 
Qld
4305</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Chris Weekes</othercollaboratorname>
      <othercollaboratoraddress>Trainee registrar
Ipswich hospital 
P O Box 73 
Ipswich 
Qld
4305</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Term PROM is a common problem. Women have traditionally been offered oxytocin infusion. This requires intravenous fluids, continuous FHR monitoring and the woman is restricted to bed.
PG gel has been shown in a large RCT to be safe and effective but has not become widely used in the public sector.
This study will address safety and efficacy as well as womens satisfaction of the two methods of induction.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication>nil yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>West Moreton South Burnett HSD HREC</ethicname>
      <ethicaddress>WMDD HREC
School of Mental health 
Dawson House
Sumner park
Richland Qld 4077</ethicaddress>
      <ethicapprovaldate>20/11/2008</ethicapprovaldate>
      <hrec>5/09/2012</hrec>
      <ethicsubmitdate>10/09/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kassam Mahomed</name>
      <address>Senior Staff Specialist
Dept of Obstetrics
P O Box 73 
Ipswich 
Qld
4305</address>
      <phone>+61-7-38101111</phone>
      <fax />
      <email>kassam_mahomed@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kassam Mahomed</name>
      <address>Senior Staff Specialist
Dept of Obstetrics
P O Box 73 
Ipswich 
Qld
4305</address>
      <phone>+61 - 7 - 38101111</phone>
      <fax />
      <email>kassam_mahomed@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kassam mahomed</name>
      <address>Senior Staff Specialist
Dept of Obstetrics
P O Box 73 
Ipswich 
Qld
4305</address>
      <phone>+61-7-38101111</phone>
      <fax />
      <email>kassam_mahomed@health.qld.gov.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>